PerkinElmer, Inc. (PKI) Expected to Post Earnings of $0.94 Per Share

Analysts predict that PerkinElmer, Inc. (NYSE:PKI) will post $0.94 earnings per share for the current quarter, according to Zacks. Six analysts have provided estimates for PerkinElmer’s earnings, with the lowest EPS estimate coming in at $0.92 and the highest estimate coming in at $0.95. PerkinElmer posted earnings per share of $0.83 during the same quarter last year, which indicates a positive year-over-year growth rate of 13.3%. The firm is expected to announce its next earnings results on Thursday, February 1st.

According to Zacks, analysts expect that PerkinElmer will report full year earnings of $2.89 per share for the current financial year, with EPS estimates ranging from $2.87 to $2.92. For the next fiscal year, analysts expect that the firm will report earnings of $3.16 per share, with EPS estimates ranging from $3.13 to $3.20. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover PerkinElmer.

Several analysts recently weighed in on PKI shares. Robert W. Baird reissued a “buy” rating and set a $72.00 price target on shares of PerkinElmer in a report on Friday, October 20th. Citigroup raised their price objective on PerkinElmer from $67.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, August 7th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $81.00 price objective on shares of PerkinElmer in a research note on Friday, August 4th. Cowen reaffirmed a “hold” rating and set a $70.00 price objective on shares of PerkinElmer in a research note on Friday, September 1st. Finally, Jefferies Group reaffirmed a “hold” rating and set a $70.00 price objective on shares of PerkinElmer in a research note on Friday, October 20th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $68.64.

In other PerkinElmer news, Director Nicholas A. Lopardo sold 24,050 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $70.72, for a total transaction of $1,700,816.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter Barrett sold 7,071 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.07, for a total transaction of $502,535.97. Following the completion of the transaction, the director now owns 26,271 shares of the company’s stock, valued at approximately $1,867,079.97. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can lifted its holdings in shares of PerkinElmer by 15.1% during the 2nd quarter. Bank of Montreal Can now owns 37,753 shares of the medical research company’s stock worth $2,572,000 after acquiring an additional 4,955 shares during the period. Creative Planning lifted its holdings in shares of PerkinElmer by 108.3% during the 2nd quarter. Creative Planning now owns 4,032 shares of the medical research company’s stock worth $275,000 after acquiring an additional 2,096 shares during the period. LS Investment Advisors LLC lifted its holdings in shares of PerkinElmer by 2.1% during the 2nd quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock worth $196,000 after acquiring an additional 60 shares during the period. Louisiana State Employees Retirement System lifted its holdings in shares of PerkinElmer by 1.5% during the 2nd quarter. Louisiana State Employees Retirement System now owns 6,800 shares of the medical research company’s stock worth $463,000 after acquiring an additional 100 shares during the period. Finally, Aperio Group LLC raised its holdings in PerkinElmer by 17.4% in the second quarter. Aperio Group LLC now owns 53,525 shares of the medical research company’s stock valued at $3,647,000 after buying an additional 7,945 shares during the period. Hedge funds and other institutional investors own 91.66% of the company’s stock.

PerkinElmer (NYSE:PKI) traded down $0.60 during trading hours on Friday, hitting $73.08. The company had a trading volume of 163,433 shares, compared to its average volume of 632,139. The company has a debt-to-equity ratio of 0.44, a quick ratio of 2.09 and a current ratio of 2.59. The company has a market capitalization of $8,070.00, a P/E ratio of 26.55, a PEG ratio of 2.21 and a beta of 0.77. PerkinElmer has a fifty-two week low of $50.51 and a fifty-two week high of $74.11.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 9th. Shareholders of record on Friday, January 19th will be issued a $0.07 dividend. The ex-dividend date is Thursday, January 18th. This represents a $0.28 annualized dividend and a yield of 0.38%. PerkinElmer’s dividend payout ratio (DPR) is presently 12.67%.

TRADEMARK VIOLATION NOTICE: “PerkinElmer, Inc. (PKI) Expected to Post Earnings of $0.94 Per Share” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/01/perkinelmer-inc-pki-expected-to-post-earnings-of-0-94-per-share.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply